Tauhid Islam1, Tom Hiatt1, Cornelia Hennig1, Nobuyuki Nishikiori1. 1. Stop TB and Leprosy Elimination, Division of Communicable Diseases, World Health Organization Regional Office for the Western Pacific, Manila, Philippines .
Abstract
OBJECTIVE: To review the latest information about tuberculosis (TB) drug resistance and programmatic management of drug-resistant TB in the Western Pacific Region of the World Health Organization (WHO). METHODS: We analysed routine data reported by countries to WHO from 2007 to 2013, focusing on data from the following: surveillance and surveys of drug resistance, management of drug-resistant TB and financing related to multidrug-resistant TB (MDR-TB) management. RESULTS: In the Western Pacific Region, 4% (95% confidence interval [CI]: 3-6) of new and 22% (95% CI: 18-26) of previously treated TB cases were estimated to have MDR-TB; this means that in 2013, there were an estimated 71,000 (95% CI: 47,000-94,000) MDR-TB cases among notified pulmonary TB cases in this Region. The coverage of drug susceptibility testing (DST) among new and previously treated TB cases was 3% and 20%, respectively. In 2013, 11,153 cases were notified--16% of the estimated MDR-TB cases. Among the notified cases, 6926 or 62% were enrolled in treatment. Among all enrolled MDR-TB cases, 34% had second-line DST and of these, 13% were resistant to fluoroquinolones (FQ) and/or second-line injectable agents. The 2011 cohort of MDR-TB showed a 52% treatment success. Over the last five years, case notification and enrolment have increased more than five times, but the gap between notification and enrolment widened. DISCUSSION: The increasing trend in detection and enrolment of MDR-TB cases demonstrates readiness to scale up programmatic management of drug-resistant TB at the country level. However, considerable challenges remain.
OBJECTIVE: To review the latest information about tuberculosis (TB) drug resistance and programmatic management of drug-resistant TB in the Western Pacific Region of the World Health Organization (WHO). METHODS: We analysed routine data reported by countries to WHO from 2007 to 2013, focusing on data from the following: surveillance and surveys of drug resistance, management of drug-resistant TB and financing related to multidrug-resistant TB (MDR-TB) management. RESULTS: In the Western Pacific Region, 4% (95% confidence interval [CI]: 3-6) of new and 22% (95% CI: 18-26) of previously treated TB cases were estimated to have MDR-TB; this means that in 2013, there were an estimated 71,000 (95% CI: 47,000-94,000) MDR-TB cases among notified pulmonary TB cases in this Region. The coverage of drug susceptibility testing (DST) among new and previously treated TB cases was 3% and 20%, respectively. In 2013, 11,153 cases were notified--16% of the estimated MDR-TB cases. Among the notified cases, 6926 or 62% were enrolled in treatment. Among all enrolled MDR-TB cases, 34% had second-line DST and of these, 13% were resistant to fluoroquinolones (FQ) and/or second-line injectable agents. The 2011 cohort of MDR-TB showed a 52% treatment success. Over the last five years, case notification and enrolment have increased more than five times, but the gap between notification and enrolment widened. DISCUSSION: The increasing trend in detection and enrolment of MDR-TB cases demonstrates readiness to scale up programmatic management of drug-resistant TB at the country level. However, considerable challenges remain.
Authors: E Nathanson; R Gupta; P Huamani; V Leimane; A D Pasechnikov; T E Tupasi; K Vink; E Jaramillo; M A Espinal Journal: Int J Tuberc Lung Dis Date: 2004-11 Impact factor: 2.373
Authors: Ibrahim Abubakar; Matteo Zignol; Dennis Falzon; Mario Raviglione; Lucica Ditiu; Susan Masham; Ifedayo Adetifa; Nathan Ford; Helen Cox; Stephen D Lawn; Ben J Marais; Timothy D McHugh; Peter Mwaba; Matthew Bates; Marc Lipman; Lynn Zijenah; Simon Logan; Ruth McNerney; Adam Zumla; Krishna Sarda; Payam Nahid; Michael Hoelscher; Michel Pletschette; Ziad A Memish; Peter Kim; Richard Hafner; Stewart Cole; Giovanni Battista Migliori; Markus Maeurer; Marco Schito; Alimuddin Zumla Journal: Lancet Infect Dis Date: 2013-03-24 Impact factor: 25.071
Authors: T Islam; B J Marais; N V Nhung; C-Y Chiang; W W Yew; T Yoshiyama; N R Mira; J van den Broek; R Lumb; N Nishikiori; L B Reichman Journal: Int J Infect Dis Date: 2015-03 Impact factor: 3.623
Authors: Kerri Viney; Chris Lowbridge; Fukushi Morishita; Kalpeshsinh Rahevar; Kyung H Oh; Tauhid Islam; Ben J Marais Journal: Bull World Health Organ Date: 2021-03-02 Impact factor: 9.408
Authors: Paul Aia; Margaret Kal; Evelyn Lavu; Lucy N John; Karen Johnson; Chris Coulter; Julia Ershova; Olga Tosas; Matteo Zignol; Shalala Ahmadova; Tauhid Islam Journal: PLoS One Date: 2016-03-22 Impact factor: 3.240